- Conditions
- Sleep Onset Latency
- Interventions
- Amber Tinted Glasses, Clear Glasses, Smart Lightbulbs
- Device
- Lead sponsor
- University of Arizona
- Other
- Eligibility
- 60 Months to 83 Months
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Tucson, Arizona
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 260
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- HIV Infections
- Interventions
- Family Centered Advanced Care Planning (FCACP) sessions, Health education control sessions
- Behavioral
- Lead sponsor
- Maureen Lyon
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 82 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Type 2 Diabetes
- Interventions
- Communal Coping Intervention, Diabetes Education
- Behavioral
- Lead sponsor
- Carnegie Mellon University
- Other
- Eligibility
- Not listed
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Depression, Anxiety, Visual Impairment, Adjustment, Adjustment Disorder With Anxious Mood, Adjustment Disorder With Depressed Mood, Blindness, Acquired, Blindness and Low Vision, Vision Loss
- Interventions
- Integrated Cognitive Behavioral Therapy (CBT) & Mindfulness Group Intervention for Adjustment to Vision Loss
- Behavioral
- Lead sponsor
- The Chicago Lighthouse
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Venous Thromboembolism
- Interventions
- Rivaroxaban (Xarelto, BAY59-7939), Standard of Care
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- Up to 17 Years
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 19 more
- Conditions
- B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
- Interventions
- Cyclophosphamide, Doxorubicin, Etoposide, Prednisone, Rituximab, Tafasitamab, Vincristine, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Lumbar Puncture, Biospecimen Collection
- Drug · Biological · Procedure
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2031
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Older Adults (50-90 Years), Mental Health, Depression and Suicide Ideation, Social Functioning, Quality of Life, Thwarted Belongingness, Perceived Burdensomeness
- Interventions
- Standardized and manualized warm calls from providers trained in the BE training, Standardized and manualized warm calls from providers trained in the BE training + ASIST training
- Behavioral
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Paranoia, Schizophrenia, Schizoaffective Disorder
- Interventions
- intranasal spray with oxytocin, nasal spray without oxytocin
- Drug · Other
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- methylphenidate, placebo
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 21 Years to 55 Years
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1986 – 1994
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Bronchopulmonary Dysplasia
- Interventions
- Synchronized HFNC at 6 liters per minute (LPM), Continuous HFNC at 6 liters per minute (LPM), Synchronized HFNC at 8 liters per minute (LPM), Continuous HFNC at 8 liters per minute (LPM)
- Other
- Lead sponsor
- University of Arkansas
- Other
- Eligibility
- 28 Days to 1 Year
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- Psychiatric Disorder, Mental Health Disorder, Stress, Adjustment Disorders
- Interventions
- No interventions
- Other
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 605 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma
- Interventions
- Campath, Rituximab, EPOCH
- Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2021
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Diffuse Large B Cell Lymphoma Relapsed, Diffuse Large B Cell Lymphoma Refractory
- Interventions
- Ibrutinib, DA-EPOCH-R, Lenalidomide
- Drug
- Lead sponsor
- Pharmacyclics LLC.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 10
- States / cities
- Duarte, California • Los Angeles, California • Orange, California + 7 more
- Conditions
- Psychosocial Adjustment
- Interventions
- Not listed
- Lead sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- NIH
- Eligibility
- 10 Months to 4 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2015
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- COVID-19, Immunosuppression, Vaccine Response Impaired
- Interventions
- Reduction in antimetabolite immunosuppression
- Drug
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Group Therapy
- Behavioral
- Lead sponsor
- Children's Hospital and Health System Foundation, Wisconsin
- Other
- Eligibility
- 13 Years to 17 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Embolism, Thrombosis
- Interventions
- Idrabiotaparinux sodium, Warfarin, Placebo (for idrabiotaparinux sodium), Avidin, Placebo (for warfarin), Enoxaparin
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,202 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Endometrial Carcinoma, Stage 0 Fallopian Tube Cancer AJCC v7, Stage I Fallopian Tube Cancer AJCC v6 and v7, Stage I Ovarian Cancer AJCC v6 and v7, Stage IA Fallopian Tube Cancer AJCC v6 and v7, Stage IA Ovarian Cancer AJCC v6 and v7, Stage IB Fallopian Tube Cancer AJCC v6 and v7, Stage IB Ovarian Cancer AJCC v6 and v7, Stage IC Fallopian Tube Cancer AJCC v6 and v7, Stage IC Ovarian Cancer AJCC v6 and v7, Stage II Cervical Cancer AJCC v7, Stage II Fallopian Tube Cancer AJCC v6 and v7, Stage II Ovarian Cancer AJCC v6 and v7, Stage II Uterine Corpus Cancer AJCC v7, Stage IIA Cervical Cancer AJCC v7, Stage IIA Fallopian Tube Cancer AJCC v6 and v7, Stage IIA Ovarian Cancer AJCC V6 and v7, Stage IIA1 Cervical Cancer AJCC v7, Stage IIA2 Cervical Cancer AJCC v7, Stage IIB Cervical Cancer AJCC v6 and v7, Stage IIB Fallopian Tube Cancer AJCC v6 and v7, Stage IIB Ovarian Cancer AJCC v6 and v7, Stage IIC Fallopian Tube Cancer AJCC v6 and v7, Stage IIC Ovarian Cancer AJCC v6 and v7, Stage III Cervical Cancer AJCC v6 and v7, Stage III Fallopian Tube Cancer AJCC v7, Stage III Ovarian Cancer AJCC v6 and v7, Stage III Primary Peritoneal Cancer AJCC v7, Stage III Uterine Corpus Cancer AJCC v7, Stage IIIA Cervical Cancer AJCC v6 and v7, Stage IIIA Fallopian Tube Cancer AJCC v7, Stage IIIA Ovarian Cancer AJCC v6 and v7, Stage IIIA Primary Peritoneal Cancer AJCC v7, Stage IIIA Uterine Corpus Cancer AJCC v7, Stage IIIB Cervical Cancer AJCC v6 and v7, Stage IIIB Fallopian Tube Cancer AJCC v7, Stage IIIB Ovarian Cancer AJCC v6 and v7, Stage IIIB Primary Peritoneal Cancer AJCC v7, Stage IIIB Uterine Corpus Cancer AJCC v7, Stage IIIC Fallopian Tube Cancer AJCC v7, Stage IIIC Ovarian Cancer AJCC v6 and v7, Stage IIIC Primary Peritoneal Cancer AJCC v7, Stage IIIC Uterine Corpus Cancer AJCC v7, Stage IIIC1 Uterine Corpus Cancer AJCC v7, Stage IIIC2 Uterine Corpus Cancer AJCC v7, Stage IV Cervical Cancer AJCC v6 and v7, Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Primary Peritoneal Cancer AJCC v7, Stage IV Uterine Corpus Cancer AJCC v7, Stage IVA Cervical Cancer AJCC v6 and v7, Stage IVA Uterine Corpus Cancer AJCC v7, Stage IVB Cervical Cancer AJCC v6 and v7, Stage IVB Uterine Corpus Cancer AJCC v7, Uterine Carcinosarcoma, Uterine Corpus Sarcoma
- Interventions
- Internet-Based Intervention, Quality-of-Life Assessment, Questionnaire Administration, Survey Administration
- Other
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- New Brunswick, New Jersey
- Conditions
- Adult Burkitt Lymphoma
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Doxorubicin, Echocardiography Test, Epcoritamab, Etoposide, Magnetic Resonance Imaging, Multigated Acquisition Scan, Positron Emission Tomography, Prednisone, Rituximab, Vincristine
- Procedure · Drug · Biological
- Lead sponsor
- AIDS Malignancy Consortium
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Breast Cancer
- Interventions
- amonafide dihydrochloride
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2004
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Atrial Fibrillation
- Interventions
- Apixaban, Warfarin
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- indocyanine green, lidocaine, vinorelbine ditartrate, high performance liquid chromatography, intracellular fluorescence polarization analysis, liquid chromatography, mass spectrometry, pharmacological study
- Drug · Other
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2010
- U.S. locations
- 2
- States / cities
- Duarte, California • Pasadena, California
- Conditions
- Adjustment Disorder
- Interventions
- RE104 for Injection
- Drug
- Lead sponsor
- Reunion Neuroscience Inc
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 32
- States / cities
- Birmingham, Alabama • Tucson, Arizona • San Diego, California + 28 more
- Conditions
- Postpartum Depression, Posttraumatic Stress Disorder, Infant Behavior, Violence, Parenting
- Interventions
- Pregnant Moms' Empowerment Program, Nondirective Support Group
- Behavioral
- Lead sponsor
- University of Notre Dame
- Other
- Eligibility
- 3 Months to 55 Years · Female only
- Enrollment
- 424 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 2
- States / cities
- Notre Dame, Indiana • Memphis, Tennessee